ST-101
/ Stratus Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 04, 2025
ST-101: Manufacturing GMP-compliant HLA-compatible definitive human hematopoietic stem and progenitors cells from iPSCs using Piezo1 agonists for clinical transplant
(ASH 2025)
- "The strong pre-clinical safety and efficacy data provides support foradvancing ST-101 into human clinical trials.1 Scapin, et al. American Journal of Hematology 100.6 (2025): 963-979."
Clinical • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Immunology • Transplant Rejection • Transplantation • CD34 • HLA-DPB1 • HLA-DQB1
1 to 1
Of
1
Go to page
1